Serum brain‐derived neurotrophic factor (BDNF) concentration predicts polyneuropathy and overall survival in multiple myeloma patients
Aneta Szudy‐Szczyrek(Medical University of Lublin), Marek Hus(Medical University of Lublin), Magdalena Bury‐Kamińska(Maria Curie-Skłodowska University), Radosław Mlak(Medical University of Lublin), Martyna Podgajna(Medical University of Lublin), Marcin Mazurek(Medical University of Lublin), Michał Szczyrek(Medical University of Lublin), Iwona Homa‐Mlak(Medical University of Lublin), Teresa Małecka‐Massalska(Medical University of Lublin), Kinga Kuśmierczuk(Medical University of Lublin), Michał Mielnik(Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo), Janusz Krawczyk(Ollscoil na Gaillimhe – University of Galway)
Cited by 24
Related Papers
Belantamab Mafodotin, Bortezomib, and Dexamethasone for Multiple Myeloma
|New England Journal of Medicine|2024|162
Therapy‐related peripheral neuropathy in multiple myeloma patients
|Hematological Oncology|2014|70